Terms: = Ovarian cancer AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Treatment
24 results:
1. DFMO Improves Survival and Increases Immune Cell Infiltration in Association with MYC Downregulation in the Pancreatic Tumor Microenvironment.
Nakkina SP; Gitto SB; Beardsley JM; Pandey V; Rohr MW; Parikh JG; Phanstiel O; Altomare DA
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947972
[TBL] [Abstract] [Full Text] [Related]
2. KRAS K104 modification affects the KRAS
Chen CC; Hsu CY; Lin HY; Zeng HQ; Cheng KH; Wu CW; Tsai EM; Hsieh TH
Sci Rep; 2020 Oct; 10(1):17447. PubMed ID: 33060649
[TBL] [Abstract] [Full Text] [Related]
3. Systemic review on B-Raf
Chavda J; Bhatt H
Eur J Med Chem; 2020 Nov; 206():112675. PubMed ID: 32798788
[TBL] [Abstract] [Full Text] [Related]
4. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
Desai J; Gan H; Barrow C; Jameson M; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Parente P; Tran B; Wang L; Chen Y; Tang Z; Huang W; Wu J; Zeng D; Luo L; Solomon B
J Clin Oncol; 2020 Jul; 38(19):2140-2150. PubMed ID: 32182156
[TBL] [Abstract] [Full Text] [Related]
5. Zamzam water protects cancer cells from chemotherapy-induced apoptosis via mitogen-activated protein kinase-dependent pathway.
Siraj AK; Begum R; Melosantos R; Albalawy W; Abboud J; Siraj N; Al-Kuraya KS
Biomed Pharmacother; 2019 Oct; 118():109376. PubMed ID: 31545262
[TBL] [Abstract] [Full Text] [Related]
6. FAM83D promotes ovarian cancer progression and its potential application in diagnosis of invasive ovarian cancer.
Zhang Q; Yu S; Lok SIS; Wong AST; Jiao Y; Lee LTO
J Cell Mol Med; 2019 Jul; 23(7):4569-4581. PubMed ID: 31037837
[TBL] [Abstract] [Full Text] [Related]
7. Tyrosine Kinase Inhibitors as Potential Therapeutic Agents in the treatment of Granulosa Cell Tumors of the Ovary.
Jamieson S; Fuller PJ
Int J Gynecol Cancer; 2015 Sep; 25(7):1224-31. PubMed ID: 26067856
[TBL] [Abstract] [Full Text] [Related]
8. Ginkgo biloba extract EGb 761 exerts anti-angiogenic effects via activation of tyrosine phosphatases.
Koltermann A; Liebl J; Fürst R; Ammer H; Vollmar AM; Zahler S
J Cell Mol Med; 2009 Aug; 13(8B):2122-2130. PubMed ID: 19175691
[TBL] [Abstract] [Full Text] [Related]
9. (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor.
Yin Z; Henry EC; Gasiewicz TA
Biochemistry; 2009 Jan; 48(2):336-45. PubMed ID: 19113837
[TBL] [Abstract] [Full Text] [Related]
10. Anti-apoptotic hPEBP4 silencing promotes TRAIL-induced apoptosis of human ovarian cancer cells by activating ERK and JNK pathways.
Li P; Wang X; Li N; Kong H; Guo Z; Liu S; Cao X
Int J Mol Med; 2006 Sep; 18(3):505-10. PubMed ID: 16865237
[TBL] [Abstract] [Full Text] [Related]
11. Comparison of strategies targeting raf-1 mRNA in ovarian cancer.
Mullen P; McPhillips F; Monia BP; Smyth JF; Langdon SP
Int J Cancer; 2006 Mar; 118(6):1565-71. PubMed ID: 16184551
[TBL] [Abstract] [Full Text] [Related]
12. [The effects of genistein on epidermal growth factor receptor mediated signal transduction pathway in human ovarian carcinoma cells lines SKOV3 and its xenograft in nude mice].
Li Y; Mi C; Wu YZ; Yang SF; Yang ZQ
Zhonghua Bing Li Xue Za Zhi; 2004 Dec; 33(6):546-9. PubMed ID: 15634453
[TBL] [Abstract] [Full Text] [Related]
13. Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells.
Nishiyama N; Nori A; Malugin A; Kasuya Y; Kopecková P; Kopecek J
Cancer Res; 2003 Nov; 63(22):7876-82. PubMed ID: 14633716
[TBL] [Abstract] [Full Text] [Related]
14. [Therapeutic effects of C-erbB-2 and C-raf-1 gene combined with antisense oligodeoxynucleotide on the human ovarian carcinoma transplanted subcutaneously in nude mice].
Wu YZ; Ren QL; Li SL
Ai Zheng; 2003 Aug; 22(8):836-9. PubMed ID: 12917030
[TBL] [Abstract] [Full Text] [Related]
15. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).
Oza AM; Elit L; Swenerton K; Faught W; Ghatage P; Carey M; McIntosh L; Dorr A; Holmlund JT; Eisenhauer E;
Gynecol Oncol; 2003 Apr; 89(1):129-33. PubMed ID: 12694666
[TBL] [Abstract] [Full Text] [Related]
16. Inhibition of phosphorylation of BAD and raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel.
Mabuchi S; Ohmichi M; Kimura A; Hisamoto K; Hayakawa J; Nishio Y; Adachi K; Takahashi K; Arimoto-Ishida E; Nakatsuji Y; Tasaka K; Murata Y
J Biol Chem; 2002 Sep; 277(36):33490-500. PubMed ID: 12087097
[TBL] [Abstract] [Full Text] [Related]
17. Association of c-raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.
McPhillips F; Mullen P; Monia BP; Ritchie AA; Dorr FA; Smyth JF; Langdon SP
Br J Cancer; 2001 Nov; 85(11):1753-8. PubMed ID: 11742498
[TBL] [Abstract] [Full Text] [Related]
18. Differential impact of raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel.
Britten RA; Klein K
Anticancer Drugs; 2000 Jul; 11(6):439-43. PubMed ID: 11001384
[TBL] [Abstract] [Full Text] [Related]
19. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells.
Zeng S; Chen YZ; Fu L; Johnson KR; Fan W
Clin Cancer Res; 2000 Sep; 6(9):3766-73. PubMed ID: 10999771
[TBL] [Abstract] [Full Text] [Related]
20. raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells.
Britten RA; Perdue S; Eshpeter A; Merriam D
Oncol Rep; 2000; 7(4):821-5. PubMed ID: 10854551
[TBL] [Abstract] [Full Text] [Related]
[Next]
